<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02681991</url>
  </required_header>
  <id_info>
    <org_study_id>RNM-001</org_study_id>
    <nct_id>NCT02681991</nct_id>
  </id_info>
  <brief_title>Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      Renamezin Capsule (an oral adsorbent) lowers indoxyl sulfate levels in patient with chronic&#xD;
      renal failure.&#xD;
&#xD;
      120 patients with chronic renal failure(baseline serum creatinine:1.5-5.0mg/dl).&#xD;
&#xD;
      Renamezin is administered 6.0mg/day. The treatment period is 2 months. The change in serum&#xD;
      indoxyl sulfate will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline of Indoxyl sulfate at 8weeks</measure>
    <time_frame>0, 8weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renamezin capsule 2g, tid, PO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Renamezin capsule</intervention_name>
    <arm_group_label>test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients spontaneously written consent to participate in this clinical trial&#xD;
&#xD;
          2. men and women over age of 19&#xD;
&#xD;
          3. pre-dialysis patients with chronic renal failure stage patient for 3 months and&#xD;
             patients for holding the stable state in serum creatinine 1.5mg/dl - 5.0mg/dl&#xD;
&#xD;
          4. patients who were no noticeable change for 12weeks before screening and are expected&#xD;
             to change is not needed during therapy in the therapy of chronic renal&#xD;
             failure(medication and dose -related, diet therapy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients with passes through the digestive tract disorders&#xD;
&#xD;
          2. patients with uncontrolled constipation symptoms&#xD;
&#xD;
          3. patients suffering from digestive tract ulcers and esophageal varices&#xD;
&#xD;
          4. patients with untreated severe hypertension (DBP ≥ 120mmHg)&#xD;
&#xD;
          5. patients hospitalized with angina pectoris, cardiovascular disease or diagnosed with&#xD;
             serious arrhythmia or cerebrovascular disease within 6 months&#xD;
&#xD;
          6. patients with hepatic impairment (2 times greater than the upper limit of normal&#xD;
             levels of AST, ALT)&#xD;
&#xD;
          7. subjects with dependency on alcohol&#xD;
&#xD;
          8. patients with current infections&#xD;
&#xD;
          9. pregnant women, nursing mothers&#xD;
&#xD;
         10. Patients with a possibility of pregnancy (However, negative case can be registered)&#xD;
&#xD;
         11. patients participating in another clinical trial in addition to the current clinical&#xD;
             trial&#xD;
&#xD;
         12. Patient who do not fit the clinical trial participation the legal and mentally&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeong-Cheon Park, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Sevrance Hospital of Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gangnam Sevrance Hospital of Yonsei University</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <last_update_submitted>July 4, 2017</last_update_submitted>
  <last_update_submitted_qc>July 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Hyeong-Cheon Park</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

